MedPath

Efficacy of dobutamine infusion for exclusion of left atrial appendage thrombus

Not Applicable
Recruiting
Conditions
Atrial fibrillation
Registration Number
JPRN-jRCTs031220544
Lead Sponsor
Machino Tomoko
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Inclusion criteria for the first step
1)Patients with valvular or non-valvular atrial fibrillation (AF)
2)Patients undergoing transesophageal echocardiography (TEE) for evaluation of intracardiac thrombus before catheter ablation for AF, percutaneous left atrial appendage (LAA) occlusion, percutaneous mitral valve commissurotomy, and electrical cardioversion, or patients suspected cardiogenic stroke and undergoing TEE to evaluate intracardiac thrombus
3)Patients with a CHADS2 score of 1 or higher
4)Patients receiving anticoagulant therapy
5)Men and women over 20 years old
6)Patients with written informed consent
Inclusion criteria for the second step
7)Patients with severe blood flow stasis (spontaneous echo contrast grade of 3 or 4) in left atrium (LA) and LAA

Exclusion Criteria

Exclusion criteria for the first step
1) Patients with past history of LAA occlusion or resection
2) Patients with systolic blood pressure of 80 mmHg or less or 180 mmHg or more before the start of TEE
3) Patients with heart rate (measured by the average method) of 100 bpm or more before the start of TEE
4) Patients receiving catecholamines
5) Patients with a history of allergic reactions to dobutamine
6) Patients with hypertrophic cardiomyopathy who have intraventricular obstruction with a maximum pressure gradient of 30 mmHg or more
7) Patients with unstable angina
8) Patients with disorientation, quadriplegia, dysarthria, and visual field impairment
9) Women who are pregnant or may become pregnant
10) Patients who are judged inappropriate by the researcher
Exclusion criteria for the second step
11) Patients with obvious LAA thrombus without infusion of dobutamine
12) Patients with systolic blood pressure of 80 mmHg or less or 180 mmHg or more before the start of dobutamine infusion
13) Patients with heart rate (measured by the average method) of 100 bpm or more before the start of dobutamine infusion

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath